Record Q2 propels Anika Therapeutics to raise 2026 guidance

summarizeSummary

Anika Therapeutics reported Q2 2026 results with record Commercial Channel revenue and raised full-year guidance, but revised its 2027 forecast to exclude Hyalofast pending FDA approval.

check_boxKey Events · Earnings and Guidance · ANIK

• Record Q2 Revenue and Profitability

  Total revenue rose 16% to $32.6 million, driven by a 17% increase in Commercial Channel revenue to a record $13.9 million. Net income reached $3.3 million, and adjusted EBITDA hit $7.1 million, the highest since 2020.

• Raised Full-Year 2026 Guidance

  Anika raised its 2026 total revenue growth guidance to 5-10% (from 1-9%) and adjusted EBITDA margin to 13-17% (from 5-10%), reflecting strong first-half execution and improved operating leverage.

• Revised 2027 Revenue Forecast

  The company lowered its 2027 Commercial Channel revenue growth guidance to 5-15% (from 10-20%) and total company revenue to flat to 5% growth, adopting a new practice of excluding revenue from products not yet approved, specifically removing Hyalofast.

• Hyalofast Regulatory Uncertainty

  Anika remains in active discussions with the FDA on the Hyalofast PMA, focusing on co-primary clinical endpoints. The removal of Hyalofast from the 2027 forecast signals ongoing uncertainty around approval timing.

auto_awesomeAnalysis · ANIK · Industrial Applications And Services

The strongest quarter since 2020 saw Commercial Channel revenue hit a record $13.9 million and adjusted EBITDA reach $7.1 million. Confidence in sustained momentum drove a raise in the full-year 2026 revenue and profitability outlook. However, removing Hyalofast from the 2027 revenue forecast introduces uncertainty around the regulatory timeline for a key pipeline asset.